AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2062984
Drug: d-amphetamine (3.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (3.75, 7.5, 15 and 30 mg)
Trial: 2062984
Drug: methylphenidate (7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate (7.5, 15, 30 and 60 mg)
Trial: 2062984
Drug: diazepam (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam (5, 10, 20 and 40 mg)
Trial: 3964335
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg N-butylscopolaminium bromide (Buscopan)
Trial: 3964335
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg N-butylscopolaminium bromide (Buscopan)
Trial: 25616100
Drug: Pharmacogenomic-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic-guided warfarin treatment
Trial: 25616100
Drug: Non-PGx therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PGx therapy (control)
Trial: 11012478
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (RACM)
Trial: 11012478
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (RAC)
Trial: 11012478
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg o.m. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (OAC)
Trial: 11012478
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg o.m. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (OACM)
Trial: 1728612
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy or chemotherapy after surgery
Trial: 6731670
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole with a meal
Trial: 6731670
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole 3 or more hours after or before a meal
Trial: 31941574
Drug: Interventions based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions based on positive psychology, supportive-expressive group therapy, behavioral therapy, or mindfulness
Trial: 27411698
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro injected into lipohypertrophic tissue (LHT)
Trial: 27411698
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro injected into normal adipose tissue (NAT)
Trial: 16276244
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination drug therapy aimed at raising HDL-cholesterol
Trial: 16276244
Drug: Niacin and
RxNorm normalized name: My Favorite Niacin and Inositol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin and well-tolerated fibrates as adjunct to statins or primary therapy
Trial: 2569309
Drug: Diuretic (xipamide-triamterene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (xipamide-triamterene combination, Neotri)
Trial: 28252269
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion sonography (SIS) followed by Pipelle® sampling
Trial: 28252269
Drug: Pipelle® sampling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipelle® sampling followed by saline infusion sonography (SIS)
Trial: 26590673
Drug: Nintedanib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (200 mg twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Trial: 26590673
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Trial: 22338103
Drug: E/S +
RxNorm normalized name: Estradiol/Norethindrone Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/S + extended-release niacin (N; titrated to 2 g)
Trial: 19776570
Drug: Rinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with 20 ml of 100 mg F/l NaF mouthwash after brushing with fluoridated toothpaste (Regime B)
Trial: 19776570
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 1 g of 1,450 microg F/g NaF toothpaste followed by rinsing for 5 s with 10 ml water (Regime A)
Trial: 11835723
Drug: Moderate hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypothermia therapy (MHT) for 4-10 days
Trial: 11835723
Drug: Moderate hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypothermia therapy (MHT)
Trial: 2889460
Drug: Xamoterol 200
RxNorm normalized name: xamoterol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 200 mg orally once daily
Trial: 2889460
Drug: Xamoterol 400
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 400 mg orally once daily
Trial: 2889460
Drug: Xamoterol 600
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 600 mg orally once daily
Trial: 2889460
Drug: Xamoterol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (all doses)
Trial: 29544720
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg of morphine (M100)
Trial: 29544720
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of morphine (M200)
Trial: 22890714
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) infusion in older sedentary individuals (OS)
Trial: 22890714
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) infusion in older active individuals (OA)
Trial: 22890714
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) infusion in young sedentary individuals (Y)
Trial: 20135144
Drug: Spray bottle
RxNorm normalized name: Povidone-Iodine 100 mg in 1 mL TOPICAL SOLUTION [Prep SolutionWith Spray Bottle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray bottle (SB)
Trial: 18056004
Drug: G-CSF from
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF from day 6 after induction chemotherapy
Trial: 18056004
Drug: G-CSF from
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF from day 12 after induction chemotherapy
Trial: 12127639
Drug: Intra-amniotic injection
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic injection of 40 mg PGF2alpha
Trial: 12127639
Drug: Intravaginal application
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal application of 200 mcg misoprostol (12 hourly doses, max 4 doses)
Trial: 630793
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) 100 mg with concurrent lithium therapy (900 mg/day for 7 days)
Trial: 630793
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) 100 mg without concurrent lithium therapy
Trial: 19624698
Drug: Intervention schools
RxNorm normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention schools (oral health promotion programme)
Trial: 9660419
Drug: Standard long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard long protocol of SC leuprolide acetate (group L)
Trial: 9660419
Drug: Monthly injection
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly injection of leuprolide acetate depot for 4 months (group D)
Trial: 9660419
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L and D)
Trial: 8005563
Drug: Pirenzepine (PZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PZ) low dose (50 mg at 22 h)
Trial: 8005563
Drug: Pirenzepine (PZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PZ) high dose (50 mg at 8 h plus 100 mg at 22 h)
Trial: 805388
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg per day
Trial: 11422755
Drug: Captopril (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (average 74 mg/day, range 12.5 to 125 mg/day)
Trial: 11422755
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment with captopril)
Trial: 8996291
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus ticlopidine (antiplatelet therapy)
Trial: 8996291
Drug: Intense anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense anticoagulant therapy (control)
Trial: 31977833
Drug: Energy gel
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy gel ingestion every 30 minutes (T1)
Trial: 31977833
Drug: Energy gel
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy gel ingestion every 45 minutes (T2)
Trial: 31977833
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel ingested during exercise (T3)
Trial: 25319120
Drug: Canrenone 50
RxNorm normalized name: canrenone
DrugBank: Canrenone (DB12221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenone 50 mg once a day for 3 months, then 50 mg twice a day
Trial: 23165696
Drug: GEn 1800
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEn 1800 mg
Trial: 23165696
Drug: GEn 2400
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEn 2400 mg
Trial: 23165696
Drug: GEn 3000
RxNorm normalized name: Epogen 3000 UNT/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEn 3000 mg
Trial: 18469255
Drug: Daidzein-7-O-beta-d-glucoside (DG)
RxNorm normalized name: trans-resveratrol 3-O-β-D-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daidzein-7-O-beta-d-glucoside (DG) (1 mg DAI aglycone equivalent/kg body weight)
Trial: 18469255
Drug: Daidzein (DAI)
DrugBank: Daidzein (DB13182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daidzein (DAI) (1 mg DAI aglycone equivalent/kg body weight)
Trial: 12587824
Drug: High avidity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High avidity anti-dsDNA antibodies in SLE patients
Trial: 12587824
Drug: ELISA method
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA method for anti-dsDNA antibody avidity determination
Trial: 12560163
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin 30/70
Trial: 9417494
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite treatment over a period of 28 days
Trial: 8338056
Drug: Intensive neoadjuvant
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive neoadjuvant chemotherapy regimen (FEC-HD) repeated every 21 days
Trial: 8338056
Drug: Intensive neoadjuvant
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive neoadjuvant chemotherapy regimen (FEC-HD)
Trial: 8338056
Drug: Intensive neoadjuvant
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive neoadjuvant chemotherapy regimen (FEC-HD) followed by modified radical mastectomy or radiotherapy
Trial: 3552076
Drug: Discontinue all
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinue all treatment after 8 months of maintenance chemotherapy
Trial: 3552076
Drug: Continue maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue maintenance therapy for a total of 3 years
Trial: 3552076
Drug: Discontinue all
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinue all therapy at 8 months
Trial: 25595508
Drug: Staff identification
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staff identification of treatment device
Trial: 18714150
Drug: Spirulina (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (8 g/day for 16 weeks)
Trial: 17361594
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (wavelength 904 nm, frequency 4000 Hz, at dose 2J per point); TENS (frequency 80 Hz, 30 minutes, pulse duration 200 micros); exercise; conventional therapy with NSAIDs (meloxicam, 15 mg per day)
Trial: 17361594
Drug: Meloxicam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (15 mg per day)
Trial: 11071328
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 microg daily, subcutaneously for the first 10 postoperative days)
Trial: 1418029
Drug: IX 800
RxNorm normalized name: PREZCOBIX 800mg-150mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IX 800 mg
Trial: 1418029
Drug: IX 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IX 1,200 mg
Trial: 31798713
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral cholecalciferol [2,000 IU per day] (experimental group)
Trial: 31798713
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without supplementation (control group)
Trial: 30282391
Drug: High-voltage pulsed
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-voltage pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds, followed by lidocaine and normal saline injection.
Trial: 30282391
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block treatment with 1.4 mL of a mixture of dexamethasone and lidocaine after 360 seconds of sham PRF treatment, followed by 0.5 mL of normal saline.
Trial: 30282391
Drug: High-voltage pulsed
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-voltage pulsed radiofrequency (PRF) treatment.
Trial: 30282391
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block treatment.
Trial: 20946621
Drug: Active physiotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active physiotherapy treatment (manual therapy and exercise plus education and advice)
Trial: 20946621
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham ultrasound and non‐therapeutic gel)
Trial: 12154207
Drug: Leflunomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (100 mg initially, then 20 mg/day)
Trial: 12154207
Drug: Methotrexate (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (15-20 mg/day)
Trial: 7018680
Drug: Combination vinblastine-CCNU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vinblastine-CCNU
Trial: 7018680
Drug: Single-agent triazinate
RxNorm normalized name: BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent triazinate
Trial: 7018680
Drug: Single-agent dactinomycin
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent dactinomycin
Trial: 24399187
Drug: Cleansing formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing formulation only (Group 1)
Trial: 24399187
Drug: Cleansing solution
RxNorm normalized name: Cleansing Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing solution and moisturizing solution (Group 2)
Trial: 24399187
Drug: Cleansing formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing formulation and moisturizing formulation (Group 3)
Trial: 18991158
Drug: Cognitive-behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural group therapy (n=7)
Trial: 15804684
Drug: Active 21‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active 21‐mg nicotine patch
Trial: 15804684
Drug: Active 2‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active 2‐mg or 4-mg nicotine lozenge
Trial: 15804684
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for both patch and lozenge)
Trial: 12153829
Drug: WS 5570
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS 5570 (300 mg t.i.d.)
Trial: 2085991
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (FT) 3 g single dose
Trial: 2085991
Drug: Pipemidic acid
RxNorm normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipemidic acid (PA) 400 mg b.i.d. for seven days
Trial: 343660
Drug: Fenoterol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.4 mg t.i.d.)
Trial: 343660
Drug: Isoproterenol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (0.15 mg t.i.d.)
Trial: 29807811
Drug: Antibiotic-impregnated nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated nasal packing
Trial: 29807811
Drug: Steroid-impregnated nasal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid-impregnated nasal packing
Trial: 29807811
Drug: Saline solution-impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution-impregnated nasal packing
Trial: 28333952
Drug: OM-85 (3.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-85 (3.5mg daily for 9 months)
Trial: 24444038
Drug: T1DM-G (HbA1c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1DM-G (HbA1c ≤ 7.5%)
Trial: 24444038
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (T1DM-G, T1DM-P, controls)
Trial: 21808844
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 ml/kg orange flavored juice)
Trial: 10759039
Drug: Single-session (SS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session (SS) treatment
Trial: 10759039
Drug: Treatment-as-needed (TAN)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-needed (TAN)
Trial: 8832303
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid with glycine (test formulation)
Trial: 8832303
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid without glycine (reference formulation)
Trial: 20920045
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro protamine suspension (ILPS) injected once or twice daily
Trial: 20920045
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine injected once daily
Trial: 15804248
Drug: Oral creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral creatine (Cr) monohydrate at a dosage of 150 mg/kg body weight/day
Trial: 12519334
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of ITI implants (6 weeks healing)
Trial: 12519334
Drug: Conventional loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional loading of ITI implants (12 weeks healing)
Trial: 7201816
Drug: Syracerin (steroid-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syracerin (steroid-free partner drug) applied at 4-13-day intervals
Trial: 7201816
Drug: Interval application
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval application of topical corticoids